Skip to main content

Table 5 Summary of the most important published studies on observation management of desmoid tumor patients

From: Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors

Study

Patients (n)

Abdominal/ Extra-abdominal (n)

Primary/Recurrent (n)

Median tumor size (cm)

Median follow-up (months)

Observation alone (n)

PD (n, %)

SD to PR (n, %)

Regression (n, %)

Tumor behavior

Comparison of PFS between observation and other treatments

Bonvalot et al. [12]

112

46/66

112/0

6

76

11

3 (27%)

NR

NR

NR

NR

Fiore et al. [3]

142

48/94

74/68

6

33

83

33 (40%)

47 (57%)

3 (4%)

47% PFS at 60 months

No difference in PFS between observation and chemotherapy

Barbier et al. [13]

26

0/26

11/15

NR

22

26

1 (4%)

24 (92%)

1 (4%)

Median time to stabilization 14 months

NR

Salas et al. [14]

426

120/306

426/0

7

52

27

6 (22%)

16 (59%)

5 (19%)

Median delay to progression 19.7 months

NR

Briand et al. [15]

73

0/73

31/24

7.5

73

55

5 (9%)

42 (76%)

5 (9%)

Median time to stabilization 9 months

NR

Huang et al. [16]

214

104/100

153/61

5.5

45

20

4 (20%)

14 (70%)

2 (10%)

Median delay to progression 15.3 months

NR

Park et al. [17]

47

7/40

47/0

8

36

20

1 (5%)

18 (90%)

1 (5%)

92% PFS at 36 months

Superior PFS in observation compared to surgery

Burtenshaw et al. [18]

213

213/0

195/18

6

54

63

4 (6%)

36 (57%)

23 (37%)

NR

NR

Penel et al. [19]

771

374/397

NR

5.7

32

388

117 (30%)

NR

NR

58% PFS at 24 months

No difference in PFS between observation and surgery

Orbach et al. [20]

154

NR

NR

NR

21

54

32 (59%)

9 (17%)

4 (7%)

NR

No difference in PFS between observation, surgery and chemotherapy

Cassidy et al. [21]

160

84/76

NR

4.7

15

37

10 (27%)

NR

NR

NR

NR

van Broekhoven et al. [22]

91

25/66

NR

NR

16

37

5 (14%)

25 (68%)

2 (5%)

NR

NR

van Houdt et al. [23]

168

76/92

NR

5.9

41

168

60 (36%)

60 (36%)

45 (27%)

NR

NR

Turner et al. [24]

103

42/61

NR

6.2

35

50

21 (42%)

29 (58%)

0

38% PFS at 36 months

NR

de Bruyns et al. [25]

227

89/138

NR

5.4

77

55

13 (24%)

20 (36%)

22 (40%)

71% PFS at 24 months

NR

  1. PD progression disease, SD stable disease, PR partial response, PFS progression-free survival, NR not reported